Cancer
BRAF and MEK inhibitors
Targeted drugs for tumours with a BRAF V600 mutation, about half of melanomas: a BRAF inhibitor combined with a MEK inhibitor blocks the MAPK pathway at two points.
آلية العمل
- BRAF V600E is a constantly active kinase that signals through MEK and ERK to drive proliferation.
- Vemurafenib, dabrafenib and encorafenib inhibit mutant BRAF; trametinib, cobimetinib and binimetinib inhibit MEK downstream.
- Combining them gives deeper responses and delays resistance; it also prevents the skin tumours that BRAF inhibitors alone provoke by paradoxically activating the pathway in normal cells.
الأهداف الجزيئية
- Mutant BRAF kinase: Inhibitor
- MEK1/2: Inhibitor
أدوية BRAF and MEK inhibitors
- Dabrafenib with trametinib
- Vemurafenib with cobimetinib
- Encorafenib with binimetinib
الاستخدامات العلاجية
- BRAF V600-mutant advanced melanoma, and after surgery for high-risk stage III
- BRAF-mutant lung cancer and colorectal cancer (encorafenib with an anti-EGFR antibody)
الأمراض التي يعالجها
الآثار الجانبية
- Fever (dabrafenib)
- Photosensitivity and rash (vemurafenib)
- Cutaneous squamous cell carcinomas, mainly with a BRAF inhibitor alone
- Reduced ejection fraction and retinal problems (MEK inhibitors)
موانع الاستعمال حسب الحالة
- Heart failure (MEK inhibitors) (بحذر): They can reduce the ejection fraction.
- Pregnancy (ممنوع): They harm the fetus.
- Long QT (بحذر): Vemurafenib prolongs the QT interval.
محاذير وتداخلات أخرى
- They are only for tumours with a BRAF V600 mutation; in BRAF wild-type tumours they can accelerate growth.
موضوعات مرتبطة
مكتوب من
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Kinase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, BRAF & MEK inhibitors
مرجع تعليمي، وليس استشارة طبية أو تشخيصاً أو علاجاً.